CN Patent

CN106554403B — 艾塞那肽修饰物及其用途

Assigned to Borui Biomedical Suzhou Co ltd · Expires 2021-08-31 · 5y expired

What this patent protects

本发明公开了一种通过亲水性连接臂将艾塞那肽和末端带羧基的脂肪链连接起来的艾塞那肽修饰物，及其在制备作为GLP‑1受体激动剂的药物中的用途；在制备用于预防和/或治疗与GLP‑1受体活性低下相关的疾病和/或症状的药物中的用途；在制备用于糖代谢相关的疾病和/或症状的药物中的用途；在制备用于糖尿病的药物中的用途；在制备用于脂肪肝的药物中的用途；在制备用于减肥的药物中的用途。

USPTO Abstract

本发明公开了一种通过亲水性连接臂将艾塞那肽和末端带羧基的脂肪链连接起来的艾塞那肽修饰物，及其在制备作为GLP‑1受体激动剂的药物中的用途；在制备用于预防和/或治疗与GLP‑1受体活性低下相关的疾病和/或症状的药物中的用途；在制备用于糖代谢相关的疾病和/或症状的药物中的用途；在制备用于糖尿病的药物中的用途；在制备用于脂肪肝的药物中的用途；在制备用于减肥的药物中的用途。

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CN106554403B
Jurisdiction: CN
Classification: —
Expires: 2021-08-31
Drug substance claim: No
Drug product claim: No
Assignee: Borui Biomedical Suzhou Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.